IDEAYA Biosciences Reports Darovasertib and Crizotinib Combo Doubles Survival in Metastatic Uveal Melanoma Trial
Reuters
Oct 20
<a href="https://laohu8.com/S/IDYA">IDEAYA Biosciences</a> Reports Darovasertib and Crizotinib Combo Doubles Survival in Metastatic Uveal Melanoma Trial
IDEAYA Biosciences Inc. announced positive results from its Phase 1/2 clinical trial (OptimUM-01) evaluating the combination of darovasertib and crizotinib in first-line treatment of metastatic uveal melanoma. The combination demonstrated a median overall survival of 21.1 months, compared to a historical median overall survival of approximately 12 months reported in published meta-analyses for this setting. Additional results included a median progression free survival of 7.0 months, an overall response rate of 34% by RECIST 1.1, a median duration of response of 9 months, and a disease control rate of 90%. The company is also conducting the registration-enabling Phase 2/3 OptimUM-02 trial in first-line HLA*A2:01-negative metastatic uveal melanoma and anticipates reporting median progression free survival data from this trial by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing. The summary of the data was presented at the 2025 Society for Melanoma Research Congress, and a presentation summary will be available on the Investor Relations section of IDEAYA's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF01431) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.